From Technology to Quality Control: Key R&D Points and Performance Evaluation of Respiratory Syncytial Virus Antigen Detection Kits (Colloidal Gold Method)

Principles of Colloidal Gold Immunochromatography and Selection of Antigen Targets

The respiratory syncytial virus antigen detection kit (colloidal gold method) uses a nitrocellulose membrane as the solid phase carrier and relies on capillary action to allow the sample to migrate across the membrane. Typically, the nucleoprotein (N protein) or fusion protein (F protein) of RSV is selected as the detection target because these proteins are abundant in viral particles, highly conserved, and possess good immunogenicity. During the research and development stage, it is necessary to screen paired monoclonal antibodies with high affinity and high specificity to ensure that different RSV subtypes (types A and B) can be effectively recognized. The conjugation process of antibodies to colloidal gold particles (such as pH, protein concentration, and blocking agents) directly affects detection sensitivity and stability.

Key Indicators for Kit Performance Verification

According to the "Measures for the Administration of In Vitro Diagnostic Reagent Registration" and relevant guiding principles, this kit must complete analytical performance evaluation and clinical evaluation. Analytical performance includes the limit of detection (analytical sensitivity), cross-reactivity, precision (intra-assay/inter-assay), hook effect, and sample stability, among others. Generally, cross-reactivity testing is required against common respiratory pathogens (such as influenza A/B virus, parainfluenza virus, adenovirus, other RSV subtypes, etc.) to verify specificity. Precision requires good repeatability across multiple tests, with consistent color development intensity of the C line and T line. Hook effect verification requires confirmation of no false negatives in high-titer samples. Clinical evaluation requires comparison with reference methods (such as RT-PCR or viral culture) to assess positive agreement rate and negative agreement rate, typically requiring no less than the generally accepted industry standards.

Inter-Batch Consistency Control and Manufacturing Process Stability

Key points in mass production include the preparation of colloidal gold particles, conjugated antibody concentration, membrane coating process, drying, and packaging steps. Inter-batch differences may arise from gold particle size distribution, conjugation efficiency, membrane batch variation, etc. Enterprises should establish a mature quality control system and conduct release testing on each batch of products, including sensitivity, specificity, repeatability, and accelerated stability testing. Accelerated stability testing is generally conducted at 37°C for 14-21 days to evaluate the reasonableness of the product shelf life. Among common specifications, reagent cards sealed in aluminum foil pouches can be stably stored at 2-30°C for 12-24 months, and it is recommended to use them within 1 hour after opening.

Common Influencing Factors and Usage Recommendations

In practical use, the sample type (nasopharyngeal swabs are superior to oropharyngeal swabs), sampling force, whether the sample processing solution is mixed evenly, and whether the sample loading volume is accurate can all affect the results. In addition, samples with high blood lipids, high bilirubin, etc. may produce non-specific background. Some kits may exhibit sensitivity differences for specific RSV genotypes, and epidemic strains should be included in verification during research and development. Users should carefully read the instructions and strictly follow the prescribed steps. For weakly positive results, repeat testing may be performed for confirmation. If the internal control line is faint, consideration should be given to whether the reagent has expired or the operation was improper.

Regulatory Supervision and Industry Outlook

As a Class III medical device, the respiratory syncytial virus antigen detection kit (colloidal gold method) must undergo registration approval by the National Medical Products Administration (NMPA). Future technological improvement directions may include enhanced sensitivity (such as using fluorescent microspheres or quantum dots to replace gold particles), achieving semi-quantitative or quantitative detection, and multiplex testing (simultaneous detection of RSV, influenza, COVID-19, etc.). At the public health level, rapid antigen testing helps provide early warning and monitoring of RSV outbreaks and reduces the risk of transmission.